Understanding MetALD
Metabolic Dysfunction and Alcohol-Associated Liver Disease
What Is MetALD?
MetALD is a newly defined liver disease category introduced in 2023 by a global consensus of hepatology societies (AASLD, EASL, and ALEH). It describes patients who have features of metabolic dysfunction-associated steatotic liver disease (MASLD) and also consume moderate-to-increased amounts of alcohol — recognizing that both metabolic factors and alcohol act together to damage the liver.
Before this classification, patients with both metabolic risk factors and alcohol use often fell into a diagnostic gray zone. MetALD now gives clinicians a formal category for this overlap, enabling better-targeted research and care.
Where MetALD Fits
Steatotic liver disease exists on a spectrum. MetALD sits between purely metabolic and purely alcohol-related disease:
metabolic causes
alcohol-driven
How Is MetALD Diagnosed?
A MetALD diagnosis requires both of the following:
1. MASLD Criteria
Evidence of hepatic steatosis (liver fat) plus at least one cardiometabolic risk factor:
- Overweight or obesity (BMI ≥ 25)
- Type 2 diabetes or prediabetes
- High blood pressure (hypertension)
- Elevated triglycerides (dyslipidemia)
- Low HDL cholesterol
2. Moderate Alcohol Consumption
| Weekly Intake | Daily Equivalent | |
|---|---|---|
| Women | 140 – 350 g/week | ~1.5 – 3.5 standard drinks/day |
| Men | 210 – 420 g/week | ~2 – 4.5 standard drinks/day |
Patients consuming below these thresholds with metabolic risk are classified as MASLD; those consuming above are classified as ALD.
MetALD by the Numbers
Why MetALD Matters
Patients with MetALD face a more unfavorable prognosis than those with MASLD alone. The combination of metabolic dysfunction and alcohol accelerates liver damage, increasing the risk of advanced fibrosis, cardiovascular events, and liver-related mortality.
Research shows that MetALD patients are at elevated risk for:
- Advanced fibrosis and cirrhosis — liver scarring progresses faster with dual insults
- Cardiovascular disease — 1.17× increased mortality risk
- Hepatocellular carcinoma (liver cancer)
- Type 2 diabetes and chronic kidney disease
The good news: reducing alcohol intake and managing metabolic risk factors (weight, blood sugar, lipids) can improve outcomes. Fibrosis regression has been observed in patients who make these changes.
What You Can Do
- Talk to your doctor about both your metabolic health and alcohol use — honest reporting helps guide treatment
- Get screened — a FIB-4 blood test or FibroScan can assess liver fibrosis
- Address alcohol use — even modest reductions can slow disease progression
- Manage metabolic risk factors — weight management, blood sugar control, and lipid management are critical
- Connect with support — Sober Livers offers peer support, education, and resources for people navigating alcohol-associated liver disease